Transglutaminase is a therapeutic target for oxidative stress, excitotoxicity and stroke: A new epigenetic kid on the CNS block

Journal of Cerebral Blood Flow and Metabolism

Volumn 33, Issue 6, 2013, Pages 809-818

  Basso, Manuela ^a,b   Ratan, Rajiv R ^a,b  

^a Burke Cornell Medical Research Institute   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adaptation; Epigenetics; Excitotoxicity; Gene transcription; Transglutaminases

Indexed keywords

3 NITROPROPIONIC ACID; ACTIN; BRAIN DERIVED NEUROTROPHIC FACTOR; DACTINOMYCIN; GLUCOCORTICOID; GLUTAMATE RECEPTOR; HEAT SHOCK PROTEIN 40; HISTONE H1; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; RETINOID; RNA POLYMERASE; RNA POLYMERASE II; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ASTROCYTE; BINDING SITE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL DAMAGE; CELL DEATH; CELL NUCLEUS INCLUSION BODY; CELL STRESS; CELLULAR DISTRIBUTION; CEREBROVASCULAR ACCIDENT; CHROMATIN STRUCTURE; DNA REPAIR; DNA SEQUENCE; DROSOPHILA; EPIGENETICS; EXCITOTOXICITY; GENE REPRESSION; GLIA CELL; HISTONE ACETYLATION; HOMEOSTASIS; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOLECULAR WEIGHT; NERVE REGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OXIDATIVE STRESS; PHYLOGENETIC TREE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RETINOBLASTOMA; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HUMANS; MOLECULAR TARGETED THERAPY; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; STROKE; TRANSGLUTAMINASES;

EID: 84878540524     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2013.53     Document Type: Review

References (110)

1. Calderone A, Jover T, Noh KM, Tanaka H, Yokota H, Lin Y et al. Ischemic insults derepress the gene silencer REST in neurons destined to die. J Neurosci 2003; 23: 2112-2121.
2. Qureshi IA, Mehler MF. Emerging role of epigenetics in stroke: part 1: DNA methylation and chromatin modifications. Arch Neurol 2010; 67: 1316-1322.
3. Langley B, Brochier C, Rivieccio MA. Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke. Stroke 2009; 40: 2899-2905.
4. Rivieccio MA, Brochier C, Willis DE, Walker BA, D'Annibale MA, McLaughlin K et al. HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci USA 2009; 106: 19599-19604.
5. McConoughey SJ, Basso M, Niatsetskaya ZV, Sleiman SF, Smirnova NA, Langley BC et al. Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol Med 2010; 2: 349-370.
6. Paschen W, Rohn G, Schmidt-Kastner R. Transglutaminase activity in reversible cerebral ischemia in the rat. Neurosci Lett 1990; 110: 232-236.
7. Fujita K, Ando M, Yamauchi M, Nagata Y, Honda M. Alteration of transglutaminase activity in rat and human spinal cord after neuronal degeneration. Neurochem Res 1995; 20: 1195-1201.
8. Ientile R, Caccamo D, Marciano MC, Curro M, Mannucci C, Campisi A et al. Transglutaminase activity and transglutaminase mRNA transcripts in gerbil brain ischemia. Neurosci Lett 2004; 363: 173-177.
9. Tolentino PJ, Waghray A, Wang KK, Hayes RL. Increased expression of tissue-type transglutaminase following middle cerebral artery occlusion in rats. J Neurochem 2004; 89: 1301-1307.
10. Caccamo D, Curro M, Condello S, Ferlazzo N, Ientile R. Critical role of transglutaminase and other stress proteins during neurodegenerative processes. Amino Acids 2010; 38: 653-658.
11. Gentile V, Davies PJ, Baldini A. The human tissue transglutaminase gene maps on chromosome 20q12 by in situ fluorescence hybridization. Genomics 1994; 20: 295-297.
12. Grenard P, Bates MK, Aeschlimann D. Evolution of transglutaminase genes: identification of a transglutaminase gene cluster on human chromosome 15q15. Structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z. J Biol Chem 2001; 276: 33066-33078.
13. Folk JE, Park MH, Chung SI, Schrode J, Lester EP, Cooper HL. Polyamines as physiological substrates for transglutaminases. J Biol Chem 1980; 255: 3695-3700.
14. Nemes Z, Petrovski G, Aerts M, Sergeant K, Devreese B, Fesus L. Transglutaminase- mediated intramolecular cross-linking of membrane-bound alphasynuclein promotes amyloid formation in Lewy bodies. J Biol Chem 2009; 284: 27252-27264.
15. Kiraly R, Csosz E, Kurtan T, Antus S, Szigeti K, Simon-Vecsei Z et al. Functional significance of five noncanonical Ca2+-binding sites of human transglutaminase 2 characterized by site-directed mutagenesis. FEBS J 2009; 276: 7083-7096.
16. Caccamo D, Curro M, Ferlazzo N, Condello S, Ientile R. Monitoring of transglutaminase 2 under different oxidative stress conditions. Amino Acids 2012; 42: 1037-1043.
17. Murthy SN, Iismaa S, Begg G, Freymann DM, Graham RM, Lorand L. Conserved tryptophan in the core domain of transglutaminase is essential for catalytic activity. Proc Natl Acad Sci USA 2002; 99: 2738-2742.
18. Bergamini CM, Signorini M, Poltronieri L. Inhibition of erythrocyte transglutaminase by GTP. Biochim Biophys Acta 1987; 916: 149-151.
19. Candi E, Paradisi A, Terrinoni A, Pietroni V, Oddi S, Cadot B et al. Transglutaminase 5 is regulated by guanine-adenine nucleotides. Biochem J 2004; 381(Pt 1): 313-319.
20. Thomas H, Beck K, Adamczyk M, Aeschlimann P, Langley M, Oita RC et al. Transglutaminase 6: a protein associated with central nervous system development and motor function. Amino Acids 2013; 44: 161-177.
21. Selkoe DJ, Abraham C, Ihara Y. Brain transglutaminase: in vitro crosslinking of human neurofilament proteins into insoluble polymers. Proc Natl Acad Sci USA 1982; 79: 6070-6074.
22. Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: multifunctional crosslinking enzymes that stabilize tissues. FASEB J 1991; 5: 3071-3077.
23. Mastroberardino PG, Iannicola C, Nardacci R, Bernassola F, De Laurenzi V, Melino G et al. 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ 2002; 9: 873-880.
24. Bailey CD, Johnson GV. The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. Neurobiol Aging 2006; 27: 871-879.
25. Morrison LD, Becker L, Ang LC, Kish SJ. Polyamines in human brain: regional distribution and influence of aging. J Neurochem 1995; 65: 636-642.
26. Boehm JE, Singh U, Combs C, Antonyak MA, Cerione RA. Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. J Biol Chem 2002; 277: 20127-20130.
27. Jeon JH, Choi KH, Cho SY, Kim CW, Shin DM, Kwon JC et al. Transglutaminase 2 inhibits Rb binding of human papillomavirus E7 by incorporating polyamine. EMBO J 2003; 22: 5273-5282.
28. Cordella-Miele E, Miele L, Beninati S, Mukherjee AB. Transglutaminase- catalyzed incorporation of polyamines into phospholipase A2. J Biochem 1993; 113: 164-173.
29. Shin DM, Kang J, Ha J, Kang HS, Park SC, Kim IG et al. Cystamine prevents ischemia-reperfusion injury by inhibiting polyamination of RhoA. Biochem Biophys Res Commun 2008; 365: 509-514.
30. Murthy SN, Wilson JH, Lukas TJ, Kuret J, Lorand L. Cross-linking sites of the human tau protein, probed by reactions with human transglutaminase. J Neurochem 1998; 71: 2607-2614.
31. Tucholski J, Kuret J, Johnson GV. Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination. J Neurochem 1999; 73: 1871-1880.
32. Miller ML, Johnson GV. Transglutaminase cross-linking of the tau protein. J Neurochem 1995; 65: 1760-1770.
33. Nemes Jr Z, Adany R, Balazs M, Boross P, Fesus L. Identification of cytoplasmic actin as an abundant glutaminyl substrate for tissue transglutaminase in HL-60 and U937 cells undergoing apoptosis. J Biol Chem 1997; 272: 20577-20583.
34. Gilad GM, Gilad VH. Cytotoxic effects of monodansylcadaverine and methylamine in primary cultures of rat cerebellar neurons. Int J Dev Neurosci 1986; 4: 401-405.
35. Cai D, Deng K, Mellado W, Lee J, Ratan RR, Filbin MT et al. and polyamines act downstream from cyclic AMP in overcoming inhibition of axonal growth MAG and myelin in vitro. Neuron 2002; 35: 711-719.
36. Basso M, Berlin J, Xia L, Sleiman SF, Ko B, Haskew-Layton R et al. Transglutaminase inhibition protects against oxidative stress-induced neuronal death downstream of pathological ERK activation. J Neurosci 2012; 32: 6561-6569.
37. Okauchi M, Xi G, Keep RF, Hua Y. Tissue-type transglutaminase and the effects of cystamine on intracerebral hemorrhage-induced brain edema and neurological deficits. Brain Res 2009; 1249: 229-236.
38. Nagy L, Saydak M, Shipley N, Lu S, Basilion JP, Yan ZH et al. Identification and characterization of a versatile retinoid response element (retinoic acid receptor response element-retinoid X receptor response element) in the mouse tissue transglutaminase gene promoter. J Biol Chem 1996; 271: 4355-4365.
39. Ientile R, Caccamo D, Griffin M. Tissue transglutaminase and the stress response. Amino Acids 2007; 33: 385-394.
40. Mirza A, Liu SL, Frizell E, Zhu J, Maddukuri S, Martinez J et al. A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kappaB. Am J Physiol 1997; 272(2 Pt 1): G281-G288.
41. Lu S, Saydak M, Gentile V, Stein JP, Davies PJ. Isolation and characterization of the human tissue transglutaminase gene promoter. J Biol Chem 1995; 270: 9748-9756.
42. Jang GY, Jeon JH, Cho SY, Shin DM, Kim CW, Jeong EM et al. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells. Oncogene 2010; 29: 356-367.
43. Campisi A, Caccamo D, Li Volti G, Curro M, Parisi G, Avola R et al. Glutamateevoked redox state alterations are involved in tissue transglutaminase upregulation in primary astrocyte cultures. FEBS Lett 2004; 578: 80-84.
44. Campisi A, Renis M, Russo A, Sorrenti V, Di Giacomo C, Castorina C et al. Transglutaminase activity in primary and subcultured rat astroglial cells. Neurochem Res 1992; 17: 1201-1205.
45. Caccamo D, Campisi A, Curro M, Aguennouz M, Li Volti G, Avola R et al. Nuclear factor-kappab activation is associated with glutamate-evoked tissue transglutaminase up-regulation in primary astrocyte cultures. J Neurosci Res 2005; 82: 858-865.
46. Lisak RP, Nedelkoska L, Studzinski D, Bealmear B, Xu W, Benjamins JA. Cytokines regulate neuronal gene expression: differential effects of Th1, Th2 and monocyte/ macrophage cytokines. J Neuroimmunol 2011; 238: 19-33.
47. Colak G, Johnson GV. Complete transglutaminase 2 ablation results in reduced stroke volumes and astrocytes that exhibit increased survival in response to ischemia. Neurobiol Dis 2012; 45: 1042-1050.
48. Tucholski J, Roth KA, Johnson GV. Tissue transglutaminase overexpression in the brain potentiates calcium-induced hippocampal damage. J Neurochem 2006; 97: 582-594.
49. Kuo TF, Tatsukawa H, Kojima S. New insights into the functions and localization of nuclear transglutaminase 2. FEBS J 2011; 278: 4756-4767.
50. Filiano AJ, Tucholski J, Dolan PJ, Colak G, Johnson GV. Transglutaminase 2 protects against ischemic stroke. Neurobiol Dis 2010; 39: 334-343.
51. Han JA, Park SC. Transglutaminase-dependent modulation of transcription factor Sp1 activity. Mol Cells 2000; 10: 612-618.
52. Ballestar E, Abad C, Franco L. Core histones are glutaminyl substrates for tissue transglutaminase. J Biol Chem 1996; 271: 18817-18824.
53. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006; 127: 59-69.
54. Wilhelmus MM, Grunberg SC, Bol JG, van Dam AM, Hoozemans JJ, Rozemuller AJ et al. Transglutaminases and transglutaminase-catalyzed cross-links colocalize with the pathological lesions in Alzheimer's disease brain. Brain Pathol 2009; 19: 612-622.
55. Wilhelmus MM, de Jager M, Rozemuller AJ, Breve J, Bol JG, Eckert RL et al. Transglutaminase 1 and its regulator tazarotene-induced gene 3 localize to neuronal tau inclusions in tauopathies. J Pathol 2012; 226: 132-142.
56. Kim SY, Grant P, Lee JH, Pant HC, Steinert PM. Differential expression of multiple transglutaminases in human brain. Increased expression and crosslinking by transglutaminases 1 and 2 in Alzheimer's disease. J Biol Chem 1999; 274: 30715-30721.
57. Hofer RE, SRt Wagner, Pasternak JJ, Albrecht 2nd RF, Gallagher WJ, Lanier WL. Fructose-1,6-bisphosphate and fructose-2,6-bisphosphate do not influence brain carbohydrate or high-energy phosphate metabolism in a rat model of forebrain ischemia. J Neurosurg Anesthesiol 2009; 21: 31-39.
58. Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 2002; 5: 405-414.
59. Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 2010; 11: 682-696.
60. Choi DW. Possible mechanisms limiting N-methyl-D-aspartate receptor overactivation and the therapeutic efficacy of N-methyl-D-aspartate antagonists. Stroke 1990; 21(11 Suppl): III20-III22.
61. Sattler R, Xiong Z, Lu WY, Hafner M, MacDonald JF, Tymianski M. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 1999; 284: 1845-1848.
62. Dieterich DC, Karpova A, Mikhaylova M, Zdobnova I, Konig I, Landwehr M et al. Caldendrin-Jacob: a protein liaison that couples NMDA receptor signalling to the nucleus. PLoS Biol 2008; 6: e34.
63. Peng X, Zhang Y, Zhang H, Graner S, Williams JF, Levitt ML et al. Interaction of tissue transglutaminase with nuclear transport protein importin-alpha3. FEBS Lett 1999; 446: 35-39.
64. Ientile R, Caccamo D, Macaione V, Torre V, Macaione S. NMDA-evoked excitotoxicity increases tissue transglutaminase in cerebellar granule cells. Neuroscience 2002; 115: 723-729.
65. Puddifoot C, Martel MA, Soriano FX, Camacho A, Vidal-Puig A, Wyllie DJ et al. PGC-1alpha negatively regulates extrasynaptic NMDAR activity and excitotoxicity. J Neurosci 2012; 32: 6995-7000.
66. Ryu H, Lee J, Zaman K, Kubilis J, Ferrante RJ, Ross BD et al. Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci 2003; 23: 3597-3606.
67. Saluja D, Vassallo MF, Tanese N. Distinct subdomains of human TAFII130 are required for interactions with glutamine-rich transcriptional activators. Mol Cell Biol 1998; 18: 5734-5743.
68. Bisotto S, Minorgan S, Rehfuss RP. Identification and characterization of a novel transcriptional activation domain in the CREB-binding protein. J Biol Chem 1996; 271: 17746-17750.
69. Tatsukawa H, Kojima S. Recent advances in understanding the roles of transglutaminase 2 in alcoholic steatohepatitis. Cell Biol Int 2010; 34: 325-334.
70. Lundquist JJ, Dudek SM. Differential activation of extracellular signal-regulated kinase 1 and a related complex in neuronal nuclei. Brain Cell Biol 2006; 35: 267-281.
71. Filiano AJ, Bailey CD, Tucholski J, Gundemir S, Johnson GV. Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling. FASEB J 2008; 22: 2662-2675.
72. Colak G, Keillor JW, Johnson GV. Cytosolic guanine nucledotide binding deficient form of transglutaminase 2 (R580a) potentiates cell death in oxygen glucose deprivation. PLoS ONE 2011; 6: e16665.
73. Baltan S, Bachleda A, Morrison RS, Murphy SP. Expression of histone deacetylases in cellular compartments of the mouse brain and the effects of ischemia. Transl Stroke Res 2011; 2: 411-423.
74. Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 2009; 32: 591-601.
75. Langley B, D'Annibale MA, Suh K, Ayoub I, Tolhurst A, Bastan B et al. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. J Neurosci 2008; 28: 163-176.
76. Yildirim F, Gertz K, Kronenberg G, Harms C, Fink KB, Meisel A et al. Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp Neurol 2008; 210: 531-542.
77. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 2004; 89: 1358-1367.
78. Faraco G, Pancani T, Formentini L, Mascagni P, Fossati G, Leoni F et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol 2006; 70: 1876-1884.
79. Itoh M, Hiroi T, Nishibori N, Sagara T, Her S, Lee MS et al. Trichostatin A enhances glutamate transporter GLT-1 mRNA levels in C6 glioma cells via neurosteroidmediated cell differentiation. J Mol Neurosci 2013; 49: 21-27.
80. Baltan S, Murphy SP, Danilov CA, Bachleda A, Morrison RS. Histone deacetylase inhibitors preserve white matter structure and function during ischemia by conserving ATP and reducing excitotoxicity. J Neurosci 2011; 31: 3990-3999.
81. Nunomura K, Kawakami S, Shimizu T, Hara T, Nakamura K, Terakawa Y et al. In vivo cross-linking of nucleosomal histones catalyzed by nuclear transglutaminase in starfish sperm and its induction by egg jelly triggering the acrosome reaction. Eur J Biochem 2003; 270: 3750-3759.
82. Kim JS, Huang TY, Bokoch GM. Reactive oxygen species regulate a slingshotcofilin activation pathway. Mol Biol Cell 2009; 20: 2650-2660.
83. Minamide LS, Striegl AM, Boyle JA, Meberg PJ, Bamburg Jr. Neurodegenerative stimuli induce persistent ADF/cofilin-actin rods that disrupt distal neurite function. Nat Cell Biol 2000; 2: 628-636.
84. Ashworth SL, Southgate EL, Sandoval RM, Meberg PJ, Bamburg JR, Molitoris BA. ADF/cofilin mediates actin cytoskeletal alterations in LLC-PK cells during ATP depletion. Am J Physiol Renal Physiol 2003; 284: F852-F862.
85. Hofmann WA, Stojiljkovic L, Fuchsova B, Vargas GM, Mavrommatis E, Philimonenko V et al. Actin is part of pre-initiation complexes and is necessary for transcription by RNA polymerase II. Nat Cell Biol 2004; 6: 1094-1101.
86. Obrdlik A, Kukalev A, Louvet E, Farrants AK, Caputo L, Percipalle P. The histone acetyltransferase PCAF associates with actin and hnRNP U for RNA polymerase II transcription. Mol Cell Biol 2008; 28: 6342-6357.
87. Obrdlik A, Percipalle P. The F-actin severing protein cofilin-1 is required for RNA polymerase II transcription elongation. Nucleus 2011; 2: 72-79.
88. Munsie L, Caron N, Atwal RS, Marsden I, Wild EJ, Bamburg JR et al. Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease. Hum Mol Genet 2011; 20: 1937-1951.
89. Igarashi S, Koide R, Shimohata T, Yamada M, Hayashi Y, Takano H et al. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat Genet 1998; 18: 111-117.
90. Karpuj MV, Becher MW, Steinman L. Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications. Neurochem Int 2002; 40: 31-36.
91. Van Raamsdonk JM, Pearson J, Bailey CD, Rogers DA, Johnson GV, Hayden MR et al. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem 2005; 95: 210-220.
92. Schaertl S, Prime M, Wityak J, Dominguez C, Munoz-Sanjuan I, Pacifici RE et al. A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors. J Biomol Screen 2010; 15: 478-487.
93. Wang X, Sarkar A, Cicchetti F, Yu M, Zhu A, Jokivarsi K et al. Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. J Neurol Sci 2005; 231: 57-66.
94. Lesort M, Lee M, Tucholski J, Johnson GV. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem 2003; 278: 3825-3830.
95. Borrell-Pages M, Canals JM, Cordelieres FP, Parker JA, Pineda JR, Grange G et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 2006; 116: 1410-1424.
96. Hwang IK, Yoo KY, Yi SS, Kim IY, Hwang HS, Lee KY et al. Expression of tissue-type transglutaminase (tTG) and the effect of tTG inhibitor on the hippocampal CA1 region after transient ischemia in gerbils. Brain Res 2009; 1263: 134-142.
97. Ryu H, Lee J, Hagerty SW, Soh BY, McAlpin SE, Cormier KA et al. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc Natl Acad Sci USA 2006; 103: 19176-19181.
98. Agrawal N, Pallos J, Slepko N, Apostol BL, Bodai L, Chang LW et al. Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc Natl Acad Sci USA 2005; 102: 3777-3781.
99. Siegel M, Khosla C. Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther 2007; 115: 232-245.
100. Choi K, Siegel M, Piper JL, Yuan L, Cho E, Strnad P et al. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol 2005; 12: 469-475.
101. Keillor JW. Tissue transglutaminase inhibition. Chem Biol 2005; 12: 410-412.
102. Caron NS, Munsie LN, Keillor JW, Truant R. Using FLIM-FRET to measure conformational changes of transglutaminase type 2 in live cells. PLoS ONE 2012; 7: e44159.
103. Al-Jallad HF, Myneni VD, Piercy-Kotb SA, Chabot N, Mulani A, Keillor JW et al. Plasma membrane factor XIIIA transglutaminase activity regulates osteoblast matrix secretion and deposition by affecting microtubule dynamics. PLoS ONE 2011; 6: e15893.
104. Prime ME, Andersen OA, Barker JJ, Brooks MA, Cheng RK, Toogood-Johnson I et al. Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease. J Med Chem 2012; 55: 1021-1046.
105. Gundemir S, Colak G, Tucholski J, Johnson GV. Transglutaminase 2: a molecular Swiss army knife. Biochim Biophys Acta 2012; 1823: 406-419.
106. Smirnova NA, Rakhman I, Moroz N, Basso M, Payappilly J, Kazakov S et al. Utilization of an in vivo reporter for high throughput identification of branched small molecule regulators of hypoxic adaptation. Chem Biol 2010; 17: 380-391.
107. Smirnova NA, Haskew-Layton RE, Basso M, Hushpulian DM, Payappilly JB, Speer RE et al. Development of Neh2-luciferase reporter and its application for high throughput screening and real-time monitoring of Nrf2 activators. Chem Biol 2011; 18: 752-765.
108. Iismaa SE, Mearns BM, Lorand L, Graham RM. Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol Rev 2009; 89: 991-1023.
109. Colak G, Johnson GV. Complete transglutaminase 2 ablation results in reduced stroke volumes and astrocytes that exhibit increased survival in response to ischemia. Neurobiol Dis 2012; 45: 1042-1050.
110. Walther DJ, Peter JU, Winter S, Holtje M, Paulmann N, Grohmann M et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 2003; 115: 851-862.